STAT3 and non-small cell lung carcinoma: Since IL-6 is a well-known canonical activator of the Jak2/STAT3 signaling pathway that enhances NSCLC progression [7, 23], the upstream genes controlling Jak2/STAT3 signals, namely IL-6, IL-6ST, and IL-6Rɑ, were analyzed in NSCLC cells with FXR overexpression or knockdown.